Drug and device marketing / Connecticut
Connecticut adds 3 state rules for drug and device marketing
Connecticut adds 3 rules to the 63 federal ones the checker already matches to drug and device marketing. None of them block approval; all 3 warn. The rules cite Conn. Gen. Stat. 21a-113, Conn. Gen. Stat. 21a-114 and Conn. Gen. Stat. 21a-93.
What Connecticut adds
These are the Connecticut rules whose wording is about prescription drugs, devices, approval and clearance claims and side effects. They run when Connecticut is selected in the checker.
CG-CTS-001 · Warns · Citation checked against stored text
The Connecticut Food, Drug and Cosmetic Act deems an advertisement of a drug or device false when it represents the product to have any effect in a list of named diseases, including cancer, diabetes, tumors, high blood pressure and heart disease. The exceptions are ads sent only to health professionals, appearing only in professional journals, or used for public health education by people with no commercial interest.
Source: Conn. Gen. Stat. 21a-114 ("The advertisement of a drug or device representing it to have any effect in albuminuria, appendicitis, arteriosclerosis, blood poison, bone disease"); Conn. Gen. Stat. 21a-93(5) ("the dissemination within this state, in any manner or by any means or through any medium, of any false advertisement")
Safer wording: Do not say a product cures, treats or prevents a named disease in consumer-facing copy. Describe what the product is and what it is cleared or approved for, and send disease-specific information only to health professionals.
Conn. Gen. Stat. 21a-93, Conn. Gen. Stat. 21a-114 · Needs counsel review
CG-CTS-002 · Warns · Citation checked against stored text
Connecticut treats an advertisement of a food, drug, device or cosmetic as misleading when it says or implies the product is recommended or endorsed by a federal or state government agency, unless the agency approved the statement before use.
Source: Conn. Gen. Stat. 21a-113 ("recommended or endorsed by any agency of the federal or state government shall be considered misleading")
Safer wording: Remove agency endorsement language. State only what the agency has actually cleared or approved, in the agency's own words, and keep written approval of the statement on file.
Conn. Gen. Stat. 21a-113 · Needs counsel review
CG-CTS-004 · Warns · Citation checked against stored text
Connecticut deems an advertisement of a drug or device false if it is false or misleading in any particular. No-side-effect, fully-safe and proven-by-trials claims are false in that sense unless the maker can show them.
Source: Conn. Gen. Stat. 21a-113 ("An advertisement of a food, drug, device or cosmetic shall be deemed to be false, if it is false or misleading in any particular")
Safer wording: Replace absolute safety and proof claims with the labeled risks and a cited study, or remove them.
Conn. Gen. Stat. 21a-113 · Needs counsel review
What the checker flags with Connecticut selected
None of our sample wording triggers a Connecticut rule, so no example is shown. The rules above are still part of the set.
The federal rules that still apply
63 federal and general rules matched to drug and device marketing run next to the Connecticut ones. The ones that weigh most:
CG-ABS-003 · Blocks approval · Citation checked against stored text
Claims of no risk or no side effects are unsubstantiated safety claims.
Source: FTC Act section 5; FTC Health Products Compliance Guidance; 21 CFR 202.1 (prescription drug advertising, fair balance)
Safer wording: State known risks and side effects fairly, or say who should talk to a clinician first.
21 CFR 202.1 · Needs counsel review
CG-ABS-012 · Blocks approval · Citation checked against stored text
Zero-risk, zero-pain and no-downside claims are absolute safety claims. Every treatment has risks, and they must be disclosed fairly.
Source: FTC Act section 5; FTC Health Products Compliance Guidance; 21 CFR 202.1
Safer wording: Describe the known risks and side effects, or say where they are explained, in place of claiming there are none.
21 CFR 202.1 · Needs counsel review
CG-DIS-028 · Blocks approval · Citation checked against stored text
Comparing a supplement to a GLP-1 prescription drug ("natural Mounjaro", "mimics Ozempic") claims drug-like effects on weight and blood sugar and implies the product does what an approved drug does.
Source: FDCA 201(g)(1); 21 CFR 101.93(g); FTC Act section 5; FTC Health Products Compliance Guidance
Safer wording: Do not name or compare to a prescription drug. Describe the ingredients.
21 CFR 101.93(g) · Needs counsel review
CG-RAF-002 · Blocks approval · Citation checked against stored text
Discounting and price-led promotion of prescription weight-loss treatment, such as sales events and rock-bottom prices, markets a prescription drug as a commodity and invites purchase without a clinical assessment.
Source: 21 CFR 202.1 (prescription drug advertising); FDA warning letters to telehealth firms on compounded GLP-1 marketing; FTC Act section 5. UK ASA rulings are the origin of the pattern but UK law is out of scope.
Safer wording: Do not use sales or lowest-price framing for prescription weight-loss treatment. State that treatment depends on a clinician assessment and describe fees plainly.
21 CFR 202.1 · Needs counsel review
Everything for the industry is on the drug and device marketing page, and all Connecticut rules for any industry are on the Connecticut page.
Next step
Check your Connecticut drug and device copy
Select Connecticut in the checker and every flag cites the rule and source listed above.